HOME >> MEDICINE >> NEWS
Using cocaine during pregnancy may damage developing fetuses, causing lifelong learning disabilities

New Haven, Conn. Taking cocaine during pregnancy causes possibly permanent changes in an area of the brain that governs short term memory leading to symptoms that are very much like attention deficit hyperactivity disorder, Yale researchers have found in two recent studies.

The research team in the Neuropsychopharmacology Laboratory at Yale School of Medicine found that prenatal exposure to cocaine leads to over-stimulation of the medical prefrontal cortex of the brain in the offspring, and a dramatic impairment in learning.

"Children exposed to cocaine in the womb may have a problem with excitable neurons in part of the brain that helps control attention and memory," said Bret Morrow, associate research scientist, associate clinical professor and lead author of both studies. "Potentially, this excitable prefrontal cortex may be the basis of the learning deficits in these children."

"The use of cocaine among women of childbearing age is alarmingly high," he added. "When a pregnant woman uses cocaine she also exposes her fetus to the drug. Studies have shown that these cocaine exposed children have increased occurrence of symptoms similar to those seen with attention deficit hyperactivity disorder increased distractibility, impulsivity and select learning deficits. Based on our animal studies, we are concerned the effects could very well be lifelong in humans."

The first study published in the February issue of Behavioral Brain Research involved administering cocaine to pregnant rats and then assessing short term memory in the offspring when they were adolescents and adults.

The test animals were placed in a cage with two identical objects. They were then removed from the cage for a brief interval, and then put back in with one of the former objects and a second new object. If the animal explored the new object preferentially, that was taken as evidence that the animal remembered the first object. The test is similar to one
'"/>

Contact: Jacqueline Weaver
jacqueline.weaver@yale.edu
203-432-8555
Yale University
18-Feb-2002


Page: 1 2

Related medicine news :

1. Using the internets power and anonymity to reduce problem drinking
2. Using celebrities to market drugs and diseases: whats the problem?
3. Using over-the-counter drugs to treat upper respiratory infections may save $4.75 billion annually
4. Using smart fluids to retrain muscles
5. Using smaller hearts could increase donor pool
6. CNS cancers and other diseases: Using proteomics to identify unique protein fingerprints
7. Using vitamin E and C supplements together may reduce risk of Alzheimer disease
8. Using fMRI technology to understand hyperlexia
9. Using their heads
10. Using naltrexone to treat alcoholics with a Mediterranean drinking pattern
11. Using PET scan technology to study alcohols effects on the brain

Post Your Comments:
(Date:5/22/2013)... and Los Angeles, CA (PRWEB) May 22, 2013 ... the board, The J. M. Smucker Company, and ... Achievement Awards yesterday at the GS1 General Assembly and ... California. Mr. Smucker and Mr. Wegman were recognized for ... GS1 Standards - the most broadly used supply chain ...
(Date:5/22/2013)... May 22 (HealthDay News) -- Children and teens exposed ... likely to develop cancer, according to a large, long-term ... a group of 10,000 young people who each had ... be expected to occur within 10 years, according to ... doctors should carefully weight the risks to patients when ...
(Date:5/22/2013)... available in German . ... Foundation) is establishing 11 new Research Training Groups to ... was made by the relevant Grants Committee in Bonn. ... to the new programmes for an initial period of ... 11 new Research Training Groups, the Grants Committee approved ...
(Date:5/22/2013)... run, encouraging a baby to finish the last ounce in ... Though the calories soon burn off, a bad habit remains. ... Forste found that clinical obesity at 24 months of age ... overweight at age two, it puts you on a trajectory ... and adolescence and as an adult," said Forste. "That,s a ...
(Date:5/22/2013)... May 22, 2013 The new 13-valent pneumococcal ... the previous version used prior to 2010, the 7-valent ... study published today in Vaccine . , The ... beginning in 2010 after a series of trials. These ... range of pneumococcal types than the previously used PCV7, ...
Breaking Medicine News(10 mins):Health News:Tim Smucker and Danny Wegman Honored With GS1 Lifetime Achievement Awards 2Health News:Tim Smucker and Danny Wegman Honored With GS1 Lifetime Achievement Awards 3Health News:Children Who Have CT Scans May Face Higher Cancer Risk 2Health News:DFG establishes 11 new research training groups 2Health News:DFG establishes 11 new research training groups 3Health News:DFG establishes 11 new research training groups 4Health News:DFG establishes 11 new research training groups 5Health News:Overeating learned in infancy, study suggests 2Health News:Study finds new pneumococcal vaccine appears to be as safe as previously used vaccine 2
(Date:5/22/2013)... -- Cellular Biomedicine Group (OTCQB: CBMG) today announced that it ... enrollment required for its Phase I trial to evaluate the ... Dendritic Cell) therapy for hepatocellular carcinoma (HCC), the most common ... no Severe Adverse Effect (SAE) reported. The Phase ... NIH under number NCT01828762 (click here to view) ...
(Date:5/22/2013)... May 22, 2013 PRNewswire – iBio, ... of a vaccine candidate for the newly emerged ... laboratory using the iBioLaunch™ platform. This validation milestone ... initial antigen sequence information to purification of recombinant ... ) The iBioLaunch platform eliminates the ...
(Date:5/22/2013)... TEL AVIV, Israel , May 22, 2013 /PRNewswire/ ... "Company") (TASE, NASDAQ: EMITF) announced today, further to the ... filed a motion with the Tel Aviv ... of its unsecured creditors and shareholders for the approval ... debt pursuant to a plan of arrangement (the "Arrangement") ...
Breaking Medicine Technology:Cellular Biomedicine Group Announces Enrollment Milestone for Phase I Clinical Trial for Liver Cancer 2Cellular Biomedicine Group Announces Enrollment Milestone for Phase I Clinical Trial for Liver Cancer 3iBio Technology Produces Vaccine Candidate for Recently Emerged H7N9 Influenza 2Elbit Imaging Announces the Court Decision with Respect to Filing of Plan of Arrangement with the Israeli Court 2Elbit Imaging Announces the Court Decision with Respect to Filing of Plan of Arrangement with the Israeli Court 3
Cached News: